Mental Health

CT-155, an investigational prescription digital therapeutic, was found to improve motivation, sociality, and other negative symptoms in patients with schizophrenia as an adjunct to antipsychotic treatment.

NRX-100 receives FDA fast track designation, offering hope for treating suicidal ideation in depression and bipolar disorder, addressing a critical health crisis.

Pharmacists guide pregnant women in balancing depression treatment with SSRI safety, addressing risks of untreated depression and neonatal adaptation syndrome.

Joel Stanley of Ajna Biosciences reflects on the regulatory challenges surrounding MDMA-assisted therapy, outlines lessons for future psychedelic drug trials, and emphasizes the importance of scientific rigor, interdisciplinary infrastructure, and the evolving role of pharmacists in ensuring safe clinical integration.

In the double-blind portion of Vibrance-1, alixorexton improved wakefulness while eliciting broad benefits in patient-reported outcomes.

Unique barriers can lead to psychiatric medication adherence rates as low as 26%.

Statins such as simvastatin do not have additional antidepressive effects in combination with standard escitalopram treatment in patients with comorbid major depressive disorder (MDD) and obesity.

BCPPs can address behavioral health workforce shortages and advocate for expanded access and reimbursement amid evolving legislation and treatment landscapes.

These health care professionals are crucial to optimizing safety in medication therapy, addressing policy barriers, and the collaboration with others in the field.

Lumatperone showed a 63% reduction in relapse risk for patients with schizophrenia, promising improved patient stability and care.

Gustavo Alva, MD, a board-certified psychiatrist, discusses the importance of mental health awareness among pharmacists and patients.

Manish Agrawal, MD, discusses the implementation of psilocybin-assisted therapy in a community cancer setting, highlighting its potential to provide sustained relief from depression and anxiety and its significant efficacy advantage over selective serotonin reuptake inhibitors for patients with cancer.

Megan Ehret, PharmD, MS, BCPP, FAAPP, discusses the clinical benefits of long-acting injectables for treating alcohol use disorder and psychiatric conditions, highlighting the pharmacist’s role in improving adherence, addressing stigma, and expanding access to care.

Manish Agrawal, MD, explores the evolving role of pharmacists in psychedelic-assisted therapy, highlighting ongoing efforts to develop standardized protocols and the emerging involvement of pharmacy teams in patient education and safety.

Manish Agrawal, MD, discusses the expanding influence of his group-based psychedelic therapy model in oncology and beyond, highlighting its adaptation in military posttraumatic stress disorder (PTSD) research, the sustained benefits of long-term patient integration, and growing institutional interest in psychedelic-assisted therapy.

The authors wrote that a life course approach to the treatment and prevention of depression may help reduce individual burdens of dementia.

A multidisciplinary team enhances psychiatric care by empowering community pharmacists to administer long-acting injectable antipsychotics, improving patient adherence and outcomes.

Ambulatory pharmacists innovate care delivery, enhancing patient access and outcomes through home visits and harm reduction clinics for complex health needs.

Never taking a break does more harm than good.

In a session at the 2025 Virtual Conference on Pain and Palliative Care, Isabella Zerfas, PharmD, and Abbey Galligan, PharmD, BCPS, explore effective pain management strategies for opioid use disorder (OUD) and complex persistent opioid dependence.

The treatment could hold significant potential for major depressive disorder

With Oregon, Colorado, and New Mexico legalizing psilocybin-assisted therapy, opportunities for treatment are expanding.

These findings demonstrate an association that is independent of the disease’s genetic predisposition.

These results build off prior studies which demonstrated effectiveness of Bergen 4-day treatment (B4DT) in patients with panic disorders.